Sign in

Trial result ·

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial tested a pair of drugs for hepatitis C. The drugs were sofosbuvir and velpatasvir, taken as pills each day. The people had hepatitis C but no cirrhosis. They had not been treated for it before. In all, 880 adults at public hospitals in India took part. By chance, each person got 8 weeks or 12 weeks of the drugs. Both people and doctors knew which group each person was in.

What they found

The main test was whether the virus was gone 12 weeks after the drugs ended. Some people took the drugs and had the test as planned. In that group, 410 of 415 people cleared the virus with 8 weeks. With 12 weeks, 397 of 401 cleared it. Counting all people, 414 of 443 cleared it with 8 weeks. With 12 weeks, 401 of 437 cleared it. The short course was not worse than the usual one. No one had serious harm linked to the drugs. No one stopped the drugs due to side effects.

What it means for patients

The authors say 8 weeks worked about as well as 12 weeks. This was in adults with hepatitis C and no cirrhosis. They say this backs a shorter course for such people.

Why it is not certain yet

The trial was done only in India. It only took in people who had not been treated before. People with cirrhosis were not part of it. People with other infections as well were also left out. Both groups knew which course they got. Some people did not finish the drugs and the test.

Source

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

PubMed · PMID 42815507

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Hepatitis C publications